Pfizer Corporation

Christopher Ryan Butler

Michael Aaron Brodney

Brian Thomas O'Neill

Elizabeth Mary Beck

Lei Zhang

Erik Alphie LaChapelle

Laura Ann McAllister

Christopher John Helal

Patrick Robert Verhoest

Bruce Nelsen Rogers

Jennifer Elizabeth Davoren

Adam Matthew Gilbert

Steven Victor O'Neil

Gabriela Barreiro

Qingyi Yang

Damien Webb

Brian Thomas O'neill

Matthew Frank Brown

Justin Ian Montgomery

Douglas Scott Johnson

Aaron Smith

Matthew Forrest Sammons

Michelle Renee Garnsey

Jana Polivkova

Xinjun J Hou

Natasha Mariam Kablaoui

Kevin Alexander Ogilvie

Peter Justin Mikochik

John Charles Murray

Erik Alphie Lachapelle

Samit Kumar Bhattacharya

Kevin James Filipski

Yuan Zhang

Bethany Lyn Kormos

Brian Kenneth Raymer

Matthew Richard Reese

Luis Angel Martinez-Alsina

Daniel Paul Uccello

Rachel Jane Roth Flach

Russell Alan Miller

Romelia Del Carmen Salomon Ferrer

Laura Ann Mcallister

Steven Victor O'neil

Kiyoyuki Omoto

Aaron Christopher Smith

The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X, X, R, R, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

Piperazine azaspiro derivatives

Described herein are methods of treating MC4R-related conditions, diseases, or disorders by administering compounds of Formula I:

Methods for antagonizing a melanocortin 4 receptor

The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: R, R, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

5,7-dihydro-pyrrolo-pyridine derivatives

Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R, R, R, X, Y, Y, Y, Yand Yare defined herein; their use as MC4R antagonists; pharmaceutical compositions containing such compounds and salts; the use of such compounds and salts to treat, for example, cachexia, anorexia, or anorexia nervosa; and intermediates and processes for preparing such compounds and salts.

Melanocortin 4 receptor antagonists and uses thereof

The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X, X, R, R, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder. 

The present invention provides, in part, compounds of Formula I, or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: (R)a, (R)b, (R)c, L, A, and E are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder. 

Dihydro-pyrrolo-pyridine derivatives

The present invention provides, in part, heterocyclic spiro compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

Heterocyclic spiro compounds as MAGL inhibitors

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, traumatic brain injury, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating MAGL-mediated diseases and disorders including, e.g., pain, an inflammatory disorder, depression, anxiety, Alzheimer's disease, a metabolic disorder, stroke, or cancer.

1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R, R, R, Rand X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

N-(2-(2-amino-6-substituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]oxazin-8a(8H)-YL)-thiazol-4-YL) amides

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variables R, Rand Rare as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

N-[2-(2-amino-6,6-disubstituted-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-YL)-1,3-thiazol-4-YL] amides

The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable Ris as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

2-amino-6-methy1-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides

Growing community of inventors

Canton, MA, United States of America

Christopher Ryan Butler